InvestorsHub Logo
Followers 9
Posts 233
Boards Moderated 0
Alias Born 03/07/2011

Re: cjgaddy post# 231106

Thursday, 08/20/2015 7:01:13 PM

Thursday, August 20, 2015 7:01:13 PM

Post# of 346299
it appears there had been a trial for ramucirumab along with docetaxel for HER2-negative, advanced breast cancer which did not produce the expected halt in disease progression.

After a median follow-up of 16.2 months, progression-free survival was 9.5 months in the ramucirumab arm and 8.2 months in the control arm.

Wonder if a combo trial with Bavi thrown in would be beneficial to a study like this.

http://www.news-medical.net/news/20131216/Combination-of-ramucirumab-and-docetaxel-fails-to-delay-advanced-breast-cancer-progression.aspx
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News